Related Experiment Videos
[Efficacy of sultamicillin fine granules in pyoderma, particularly in impetigo contagiosa]
Y Tokuda1, T Kawashima, Y Inoue
1Department of Dermatology, Tokyo Medical College.
Abstract:
Sultamicillin fine granules were administered orally to 21 patients with impetigo contagiosa and 1 patient with erysipelas, and its clinical efficacy and safety were assessed. The dosage was 10-30 mg/kg daily. Clinical efficacies of impetigo contagiosa were "excellent" in 20 cases and "fair" in 1 case, with an overall efficacy rate of 95%. The result of treatment in erysipelas was "good". Out of 19 strains of Staphylococcus aureus isolated from foci, 17 strains had high beta-lactamase activities. In these 17 strains, sensitivity to the drug was 2-32-fold higher than to ampicillin, and in 14 out of these 17 strains 4-8-fold higher sensitivity was noted. As side effects, mild diarrhea was seen in 2 patients, but those recovered spontaneously in 3-4 days without particular treatment.
Insights
Sultamicillin fine granules effectively treated impetigo contagiosa (95% efficacy) and erysipelas. This antibiotic showed higher sensitivity against beta-lactamase producing Staphylococcus aureus compared to ampicillin.
Area of Science:
- Dermatology
- Infectious Diseases
- Pharmacology
Background:
- Bacterial skin infections like impetigo contagiosa and erysipelas require effective antibiotic treatment.
- Staphylococcus aureus, a common pathogen, often exhibits beta-lactamase activity, conferring resistance to certain antibiotics.
- Assessing novel antibiotic formulations for pediatric and adult use is crucial for managing skin infections.
Observation:
- Sultamicillin fine granules were administered orally to 22 patients (21 with impetigo contagiosa, 1 with erysipelas) at a dosage of 10-30 mg/kg daily.
- Clinical efficacy for impetigo contagiosa was rated 'excellent' in 20 cases and 'fair' in 1, yielding a 95% overall efficacy rate.
- The treatment for erysipelas was evaluated as 'good'.
- Out of 19 Staphylococcus aureus strains isolated, 17 demonstrated high beta-lactamase activity.
Findings:
- Sultamicillin demonstrated significantly higher sensitivity against beta-lactamase producing Staphylococcus aureus strains compared to ampicillin, with 2-32 fold increased sensitivity noted.
- Specifically, 14 out of 17 resistant strains showed 4-8 fold higher sensitivity to sultamicillin.
- Mild diarrhea was the only observed side effect, affecting 2 patients and resolving spontaneously within 3-4 days.
Implications:
- Sultamicillin represents a potentially effective therapeutic option for impetigo contagiosa and erysipelas, particularly those caused by beta-lactamase producing Staphylococcus aureus.
- The favorable safety profile and improved efficacy against resistant strains suggest sultamicillin's value in managing common bacterial skin infections.
- Further research could explore sultamicillin's role in broader dermatological and infectious disease contexts.